top of page
Developing Therapeutics Targeting ICE Regulators 

A heatmap of changes in cell behaviour following environmental change.

Image taken from Killaars et al., 2018, Adv.Sci.2019, 6, 1801483

MicroQuin focuses in-house efforts on Cancer, while progressing Anti-Virals and Neuro with the support of collaborators.

Lead Program
- Oncology

All Cancers induce an extreme ICE, which hyperactivates ICE regulators to neutralize ICE change, and promote cancer survival. MicroQuin’s therapeutics selectively inhibit cancer ICE regulators to induce death.

Cancer flow_edited.jpg

MicroQuin’s lead compound selectively binds cancerous cells in vivo to induce rapid tumor cell death (>95% in 28 day).  No toxicity or adverse effects were measured.

Cancer effect_edited.jpg

Treatment of breast cancer tumor with placebo (untreated), standard of care (Tamoxifen), or MicroQuin's therapeutics (MQ treatment). 

Oncology anchor
support by NIAID

Viruses hijacks the host cell to establish an ICE that enables them to replicate and spread. MicroQuin’s therapeutics activate ICE regulators, neutralizing viral-induced ICE changes, resulting in full viral inhibition.

Viral flow_edited.jpg

MicroQuin’s anti-virals induce >99.9% viral inhibition from a single dose, thereby stopping viral replication and spread.

Viral flow_edited.jpg
Viral anchor

Neurodegenerative disease is a ‘catch all term’ for a complex process of ICE changes that result in neurological damage. In the case of TBI, all secondary injury is caused by ICE change, enabling injury progression.

neuro flow_edited.jpg

MQ Therapeutics can reverse secondary brain injury / ICE change, transforming damaged neurons into uninjured neurons

neuro flow_edited.jpg
Neuro Anchor
bottom of page